Opendata, web and dolomites


A Streptavidin Microarray Platform for Capturing of Circulating Tumor Cells from the Blood of Cancer Patients

Total Cost €


EC-Contrib. €






Project "CAPTURE-CTC" data sheet

The following table provides information about the project.


Organization address
address: Martinistrasse 52
postcode: 20251

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙750 €
 EC max contribution 149˙750 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2016-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

The main cause of death in cancer patients is not the primary tumor but rather metastasis, which is initiated by the spread of circulating tumor cells (CTCs) in the blood. Therefore, CTCs will become a valuable diagnostic tool, once a reliable, cost-effective method is established. Research in the ongoing ERC Advanced Investigator Grant DISSECT (PI: Klaus Pantel) has revealed clear limitations of existing platforms for the detection of CTCs. The enrichment and identification of CTCs out of a blood sample is still a major challenge, mainly because the ratio between CTCs and blood cells is approximately 1:109. The proposed CAPTURE-CTC project is based on this knowledge and aimed to develop and validate a novel improved platform for CTC detection: Pumping a suspension of blood cells through a microfluidic chip, only labeled CTCs get immobilized on a micro-pattern due to strong biotin-streptavidin interaction. Single cell analysis can be performed after the cells are quantified, optically localized and extracted from the pattern with a micro-capillary. This platform will be validated on cancer patients. The detection of CTCs is a very active field, targeted by several SMEs with approaches in different stages of development and/or clinical application. However, the only FDA-cleared assay for CTC detection is the “CellSearch CTC Test” which will be the benchmark in regard to performance, validity of results and cost per test. The CellSearch system has technical limitations (e.g., EpCAM-negative CTCs are not captured and it is a closed system that allows no easy access to the captured CTCs for subsequent molecular characterization analyses). Our proposed CAPTURE-CTC system will constitute a novel platform that will overcome these important limitations and establish an easy-to-use blood test allows further downstream analyses of CTCs as a “liquid biopsy” relevant to personalized cancer medicine.


year authors and title journal last update
List of publications.
2015 Falko Brinkmann, Michael Hirtz, Anna Haller, Tobias M. Gorges, Michael J. Vellekoop, Sabine Riethdorf, Volkmar Müller, Klaus Pantel, Harald Fuchs
A Versatile Microarray Platform for Capturing Rare Cells
published pages: 15342, ISSN: 2045-2322, DOI: 10.1038/srep15342
Scientific Reports 5 2019-07-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAPTURE-CTC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAPTURE-CTC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  


The Mass Politics of Disintegration

Read More  

HOLI (2019)

Deep Learning for Holistic Inference

Read More